Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed an additional on-market repurchase of 9,100 H shares on 2 September 2026. The shares were bought at prices ranging from HKD 16.63 to HKD 16.68, for a total outlay of HKD 0.15 million.

Including this latest transaction, Haohai Biotech has acquired 655,500 H shares since the current mandate was approved on 29 May 2026. The cumulative volume represents 1.88 % of the company’s H-share count on the mandate date, against an authorised limit of 3.48 million shares.

All 655,500 repurchased shares are designated for cancellation; none will be held as treasury stock. Formal cancellation has not yet occurred, so the company’s issued share capital remains unchanged at 224.98 million ordinary shares, comprising: • 34.78 million H shares (listed on the Hong Kong Stock Exchange) • 190.20 million A shares (listed on the Shanghai Stock Exchange Sci-Tech Innovation Board) • 3.85 million A shares are recorded as treasury shares.

Under Hong Kong listing rules, Haohai Biotech is subject to a 30-day moratorium on issuing new shares or selling treasury shares, lasting until 2 October 2026.